VENCLEXTA® (venetoclax) plus rituximab will be funded from 1 December 2019 for patients with chronic lymphocytic leukaemia who have relapsed within 36 months of previous treatment. Every year in New Zealand around 120 people are diagnosed with ...
from Google Alert - health https://ift.tt/2PG5iCl
via IFTTT
0 comments:
Post a Comment